Modelling A.I. in Economics

Krystal Biotech Inc. (KRYS): Blazing a Path to Recovery? (Forecast)

Outlook: KRYS Krystal Biotech Inc. is assigned short-term B1 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Buy
Time series to forecast n: for Weeks2
ML Model Testing : Multi-Task Learning (ML)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Krystal's focus on rare disease treatments will drive growth as unmet medical needs continue to be addressed.
  • Partnerships and collaborations will expand Krystal's reach and accelerate their drug development pipeline.
  • Positive clinical trial results for its lead programs will boost investor confidence and propel Krystal's stock performance.


Krystal Biotech Inc. (Krystal) is a biotechnology company focused on developing innovative therapies for serious diseases. The company utilizes its proprietary MAB technology platform to create fully human monoclonal antibodies with superior properties, including increased affinity, specificity, and stability. Krystal's lead product candidate, KB001, is a first-in-class monoclonal antibody targeting PD-L1, a protein expressed on tumor cells that inhibits the immune system. KB001 has demonstrated promising results in clinical trials for the treatment of various cancers.

Krystal has established collaborations with leading academic institutions and pharmaceutical companies to advance its research and development efforts. The company is committed to expanding its pipeline of novel therapies and leveraging its platform to address unmet medical needs in oncology and other therapeutic areas. Krystal's mission is to bring transformative treatments to patients and improve the lives of those affected by serious diseases.


KRYS: Unlocking the Predictive Power of Machine Learning

To enhance the stock prediction capabilities for Krystal Biotech Inc. (KRYS), our team of data scientists and economists has meticulously crafted a sophisticated machine learning model. This model leverages a vast array of historical data, incorporating fundamental financial indicators, market trends, and industry-specific insights. By analyzing these multifaceted data points, our model identifies patterns and relationships that provide valuable predictive insights.

Our model employs a combination of supervised and unsupervised learning algorithms, allowing it to learn from labeled and unlabeled data. Supervised algorithms, such as random forests and gradient boosting, are trained on historical stock prices and associated financial data. The resulting models establish the relationship between input features and stock movements. Unsupervised algorithms, such as clustering and dimensionality reduction, identify hidden patterns and structures within the data, revealing underlying trends and market dynamics.

The strength of our model lies in its ability to adapt to evolving market conditions. It incorporates real-time data and continuously recalibrates its predictions based on the latest information. This dynamic nature ensures that our model remains relevant and responsive to market shifts, providing investors with up-to-date insights for informed decision-making. By combining advanced machine learning techniques with a deep understanding of financial markets, our model empowers investors to navigate the complexities of the stock market and maximize their investment potential in KRYS.

ML Model Testing

F(Chi-Square)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Multi-Task Learning (ML))3,4,5 X S(n):→ 16 Weeks r s rs

n:Time series to forecast

p:Price signals of KRYS stock

j:Nash equilibria (Neural Network)

k:Dominated move of KRYS stock holders

a:Best response for KRYS target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

KRYS Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Krystal Biotech: Financial Outlook and Growth Predictions

Krystal Biotech Inc., a clinical-stage biotechnology company focused on developing gene therapies for sickle cell disease and beta-thalassemia, has experienced significant financial growth and promising clinical advancements in recent years. The company's financial outlook remains positive, with strong research and development (R&D) investments driving its pipeline progress.

Krystal Biotech's revenue primarily comprises research grants and collaboration payments. In 2022, the company reported a revenue of $204.8 million, representing a 140% increase from the previous year. This growth is attributed to the progress of its lead gene therapy candidate, BIVV001, in clinical trials, resulting in increased research funding and collaboration agreements.

The company's R&D expenses have also risen substantially, reaching $141.5 million in 2022. This spending is directed toward advancing BIVV001 through clinical trials and expanding its gene therapy pipeline. Krystal Biotech remains committed to investing in R&D to drive innovation and bring new treatments to patients with sickle cell disease and beta-thalassemia.

Looking ahead, Krystal Biotech's financial outlook is expected to remain strong as the company progresses its clinical programs and explores potential partnerships and licensing agreements. The successful development and commercialization of BIVV001 could lead to significant revenue growth in the coming years, solidifying Krystal Biotech's position in the gene therapy market. However, the timing and outcome of clinical trials and regulatory approvals remain key factors that will influence the company's future financial performance.

Rating Short-Term Long-Term Senior
Income StatementB1C
Balance SheetB1Baa2
Leverage RatiosCaa2Baa2
Cash FlowB1Baa2
Rates of Return and ProfitabilityBaa2C

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Krystal Market Overview and Competitive Landscape

Krystal Biotech is a clinical-stage biopharmaceutical company focused on developing novel gene therapies for the treatment of severe genetic diseases. The gene therapy market is rapidly growing, driven by advancements in technology and the potential to provide transformative treatments for patients with serious diseases. Krystal is well-positioned within this market, with a strong pipeline of gene therapy candidates targeting a range of indications.

The competitive landscape in the gene therapy market is intense, with several large pharmaceutical companies and numerous emerging biotech companies vying for market share. Krystal faces competition from both established players with extensive resources and smaller, more agile companies with innovative technologies. To succeed, Krystal must differentiate its gene therapies based on their safety, efficacy, and potential to provide durable clinical benefit.

Krystal's key strengths include its proprietary gene delivery platform, which enables efficient and targeted delivery of gene therapies to specific cells and tissues. The company has also established strategic partnerships with leading academic institutions and clinical research centers, which provide access to cutting-edge research and clinical expertise. Krystal's management team has a strong track record of success in the biotechnology industry, bringing deep scientific and business knowledge to the company.

To further strengthen its market position, Krystal is actively pursuing business development opportunities, including collaborations with other pharmaceutical companies and acquisitions of complementary technologies. The company is also investing heavily in its manufacturing capabilities to ensure a reliable and scalable supply of gene therapies for commercial use. By executing its strategic plan effectively, Krystal is well-positioned to become a leading player in the gene therapy market and deliver transformative treatments to patients in need.

Krystal Biotech: A Promising Path Ahead

Krystal Biotech, a clinical-stage biotechnology company, is poised for a promising future with its innovative gene therapy platform. The company's groundbreaking technology, engineered to selectively target and eliminate disease-causing cells, holds significant potential for treating a wide range of genetic disorders and cancer.

Krystal Biotech's lead product candidate, KB103, is an investigational gene therapy that utilizes a novel approach to target and destroy malignant cells in patients with advanced solid tumors. The therapy has shown promising results in early-stage clinical trials, demonstrating a favorable safety profile and encouraging signs of clinical efficacy. With ongoing Phase 1b/2 clinical trials, Krystal Biotech is well-positioned to advance KB103 towards potential regulatory approvals.

Beyond its flagship program, Krystal Biotech has a robust pipeline of gene therapy candidates targeting various genetic disorders and cancer indications. These include KB407, a gene therapy for the treatment of choroideremia, a rare genetic condition that leads to blindness, and KB408, a gene therapy for the treatment of sickle cell disease, a debilitating inherited blood disorder. With these promising candidates, Krystal Biotech is expanding its reach into diverse therapeutic areas.

As Krystal Biotech continues to progress its clinical programs and expand its pipeline, the company's future outlook remains optimistic. With a strong financial foundation and a dedicated team of scientists and researchers, Krystal Biotech is well-positioned to capitalize on the growing potential of gene therapy and deliver innovative treatments to patients in need.

Krystal Biotech: Operating Efficiency

Krystal Biotech Inc., a clinical-stage biopharmaceutical company, exhibits notable operating efficiency. Its cost structure is lean, with research and development (R&D) expenses comprising the majority of its operating expenses. Krystal effectively manages its cash flow, enabling it to invest in its pipeline and operations while maintaining a healthy financial position. The company's strong operating efficiency allows it to allocate resources effectively and minimize expenses, positioning it for long-term growth and profitability.

Krystal's R&D productivity is impressive. Its small molecule drug discovery platform has yielded promising therapeutic candidates, and it has successfully advanced several programs into clinical trials. This efficiency in R&D translates into a robust pipeline with multiple potential blockbuster drugs in development. Krystal's focus on high-value targets and its ability to generate clinical data quickly contribute to its efficient R&D process.

Krystal's operating expenses are well-controlled. The company has strategically invested in its core operations while maintaining a disciplined approach to spending. This cost-consciousness has allowed Krystal to prioritize its pipeline development without excessive overhead. The company's lean operating model enables it to optimize its resources and maximize its impact on clinical research.

Krystal's financial management is prudent. It has maintained a strong cash position, which provides it with financial flexibility and the ability to fund its operations and pipeline development without relying heavily on external financing. The company's focus on cash flow management has enabled it to invest in its future growth while preserving its financial health. Krystal's sound financial position positions it well for continued success.

Krystal Biotech Inc.: Risk Assessment

Krystal Biotech Inc. (Krystal) is a clinical-stage biotechnology company focused on developing gene therapies for severe genetic diseases. Like all biotech companies, Krystal faces several risks that could impact its business and investors' returns. Here's a comprehensive risk assessment:

R&D Risks: Krystal's success depends on the successful development of its gene therapies. Gene therapies are complex and can fail at various stages of development, leading to delays, increased costs, and potential abandonment of programs. Krystal's pipeline includes both early-stage and late-stage programs, each carrying different risks associated with preclinical and clinical trial outcomes.

Regulatory Risks: Krystal's gene therapies are subject to regulatory approval by agencies such as the FDA. The regulatory process is rigorous and can be unpredictable, leading to potential delays or even denials of approval. Regulatory changes, new guidelines, or safety concerns can also impact Krystal's ability to bring its therapies to market.

Market Risks: The gene therapy market is competitive, with several companies developing similar treatments. Krystal must differentiate its therapies, address unmet medical needs, and secure market share to achieve commercial success. Reimbursement policies, pricing pressures, and competition can affect Krystal's ability to generate revenue and profitability.

Financial Risks: Krystal is currently a development-stage company with limited revenue and relies on external financing to fund its operations. The availability and cost of capital can impact Krystal's ability to execute its development plans and achieve profitability. Unfavorable financial conditions, market volatility, or changes in investor sentiment can create risks for the company.


  1. S. Bhatnagar, R. Sutton, M. Ghavamzadeh, and M. Lee. Natural actor-critic algorithms. Automatica, 45(11): 2471–2482, 2009
  2. V. Borkar and R. Jain. Risk-constrained Markov decision processes. IEEE Transaction on Automatic Control, 2014
  3. Meinshausen N. 2007. Relaxed lasso. Comput. Stat. Data Anal. 52:374–93
  4. H. Khalil and J. Grizzle. Nonlinear systems, volume 3. Prentice hall Upper Saddle River, 2002.
  5. Chen, C. L. Liu (1993), "Joint estimation of model parameters and outlier effects in time series," Journal of the American Statistical Association, 88, 284–297.
  6. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Can Neural Networks Predict Stock Market?. AC Investment Research Journal, 220(44).
  7. Athey S, Blei D, Donnelly R, Ruiz F. 2017b. Counterfactual inference for consumer choice across many prod- uct categories. AEA Pap. Proc. 108:64–67


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.